Pharming Group N.V. PHGUF
1.26 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
0.9545 Day range 0.9545
0.929 52-week range 2.17
- YTD
- -23.64%
- 1 year
- -17.65%
News
seekingalpha.com Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could…
globenewswire.com Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to…
globenewswire.com FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S. FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are…
globenewswire.com Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in…
globenewswire.com Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
globenewswire.com Pharming Group announces results of 2026 Annual General Meeting of Shareholders Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.
seekingalpha.com Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
globenewswire.com Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the…
globenewswire.com Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.
seekingalpha.com Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
globenewswire.com Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
seekingalpha.com Pharming Group: Crossing From Speculation To Profitability Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance,…
seekingalpha.com Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
globenewswire.com Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL)…
seekingalpha.com Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript Pharming Group N.V. ( PHAR ) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas…
seekingalpha.com Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript Pharming Group N.V. (NASDAQ:PHAR ) Q2 2025 Earnings Conference Call July 31, 2025 7:30 AM ET Executives Anurag Relan – Chief Medical Officer Fabrice Chouraqui – CEO & Executive Director Stephen Toor…
seekingalpha.com Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen…
seekingalpha.com Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer…
benzinga.com European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug On Wednesday, Pharming Group N.V. PHAR revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta…
seekingalpha.com Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript Pharming Group N.V. (NASDAQ:PHAR ) Q3 2024 Earnings Conference Call October 24, 2024 7:30 AM ET Company Participants Sijmen de Vries - Chief Executive Officer & Executive Director Stephen Toor -…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Thursday - benzinga.com Stocks That Hit 52-Week Highs On Wednesday
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Highs On Friday